Pomalidomide (CC-4047)

製品コード:S1567

For research use only.

Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

Pomalidomide (CC-4047)化学構造

CAS No. 19171-19-8

サイズ 価格(税別)
10mM (1mL in DMSO) JPY 17100
JPY 13600
JPY 63400

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(89)

製品安全説明書

E3 ligase Ligand阻害剤の選択性比較

生物活性

製品説明 Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
特性 A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
ターゲット
CRBN [5] TNF-α [1]
(PBMCs)
13 nM
体外試験

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NHzXXZhEgXSxdH;4bYNqfHliQYPzZZk> MXyxNEDPxE1? MUSyOEBp M4i2XpBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= NIrx[no9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPFI4Oyd-Mk[zN|gzPzN:L3G+
J-CD38 NVHIVY1TS3m2b4TvfIlkcXS7IFHzd4F6 NH\wbJoyOCEQvF2= NH7UTJIzPCCq M1zyepBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= NYC0UXNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN|gzPzNpPkK2N|M5Ojd|PD;hQi=>
R-CD38 MYDDfZRwfG:6aXPpeJkhSXO|YYm= MYCxNEDPxE1? MYeyOEBp M1XyN5BwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN|OEK3N{c,OjZ|M{iyO|M9N2F-
BC-3 M365NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\hN|kuOTJ3MDDuUS=> NW\leZRSPSCm NI\UTpdFVVORwrC= NXLwPFBsUUN3ME2xNFchdk1uIHnubIljcXS|IHPlcIwhUUN3ME2xNFchdk1uII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3jo[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
BCBL-1 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvkbnM{QS1zMkWwJI5O NHLlRW42KGR? Mnj1SG1UV8Li MnnDTWM2OD15NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NYX1O|A2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
JSC-1 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPZb|c{QS1zMkWwJI5O MkHrOUBl NI[0RoJFVVORwrC= M4DHbGlEPTB;M{Sgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= Ml71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
VG-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHRd2Y{QS1zMkWwJI5O MXG1JIQ> NFPaR4tFVVORwrC= NY\XcXlTUUN3ME2xNFEhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> Ml\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
UMPEL-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDufHdwOzlvMUK1NEBvVQ>? NFrJcpc2KGR? NGrjTpNFVVORwrC= M2DJOmlEPTB;M{Kgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M3z6[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
UMPEL-3 NFjQSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKzPU0yOjVyIH7N NFnWcXk2KGR? MXvEUXNQyqB? MkDuTWM2OD1zMUGgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M1TyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
BC-1 M4jkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T4SlM6NTF{NUCgcm0> M1;uVVUh\A>? MmfESG1UV8Li M2DX[2lEPTB;N{S0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 M3:ySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
BCP-1 M1LsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qwcFM6NTF{NUCgcm0> M{DybFUh\A>? MV;EUXNQyqB? MlvrTWM2OD1|OU[gcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= MojzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
APK-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX1UXFPOzlvMUK1NEBvVQ>? NXrBeGZGPSCm MlXySG1UV8Li NYPWXJAyUUN3ME2yNlYhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NWfQcnV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
RPMI8226  NXXqO2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqwMlAyNTVyIN88US=> NF3rdFU1QCCq NVXC[2JCTE2VT9Mg M4PXcWlEPTB;ODFOwG0> NYLwSlU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
OPM2  MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXwUmkxNjBzLUWwJO69VQ>? MV60PEBp MoDzSG1UV8Li MV;JR|UxRTFyIN88US=> NVTTdW5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
RPMI8226  MlPUSpVv[3Srb36gRZN{[Xl? MoHpNVAh|ryP NFvOemU1QCCq NH;ac2lFVVORwrC= MVTzeJJmdme2aHXud{BkgXSxcHzhd41q[y2wdXPs[YFzKHOqdYT0cIlv\yCxZjDtWG9TKGGwZDDwMY1VV1JicILveIVqdg>? M1:0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm3PFczLz5{NkC5O|g4OjxxYU6=
OPM2  NXj6SlRsTnWwY4Tpc44hSXO|YYm= NYS5[WdNOTBizszN MnHIOFghcA>? M3vkTmROW00EoB?= NETucXB{fHKnbnf0bIVveyCleYTvdIxie22rYz3ueYNt\WG{IIPoeZR1dGmwZzDv[kBuXE:UIHHu[EBxNW2WT2KgdJJwfGWrbh?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3Nkc,OjZyOUe4O|I9N2F-
RPMI8226 NIfR[mpHfW6ldHnvckBCe3OjeR?= NWjFSlRpOC5zLUGwJO69VQ>? NIfzR4g1KGh? NGDuVJVFVVORwrC= M3;1bolv[3KnYYPld{BXTUeIIH3SUmEh\XiycnXzd4lwdg>? MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO5PVAoRjJ3MEWzPVkxRC:jPh?=
SH-SY5Y  MVvBdI9xfG:|aYOgRZN{[Xl? NVLUS4xLOjYEoN88[{9uVA>? M3fZOVHDqGh? MojQZ4F2e2W|IIP0ZZRqe3SrY3HscJkhe2mpbnnmbYNidnRicnXkeYN1cW:wIHnuJIJwfGhiQ2DGMUBidmRiQ2DGL2NONWmwZIXj[YQh[XCxcITvd4l{yqB? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5NUK3Okc,OjR7N{WyO|Y9N2F-
JJN3 M1O3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXmcW8xNjFvMUCwJO69VQ>? M2TZdFczKGh? MYPEUXNQ Ml3SbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NFjOenc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
XG-1 M1zkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XUOVAvOS1zMECg{txO NXX1TJNQPzJiaB?= NFvCWIpFVVOR NWPKVWZjcW6qaXLpeJMh[2WubDDndo94fGh? NEPMXmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
CD138+  M4[2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvtSHQxNjFvMUCwJO69VQ>? MWS3NkBp MUPEUXNQ MUXpcohq[mm2czDj[YxtKGe{b4f0bC=> NXP5bXNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxO|g{PzhpPkKzNVc5Ozd6PD;hQi=>
XG-1 NF\sRY9HfW6ldHnvckBCe3OjeR?= NFrmRlEzNzFyMDFOwG0> NUHyZ2hTOjRiaB?= MljySG1UVw>? NFvXW|JqdmirYnn0d{BES0x|L13JVE0y|rFibWLORUBmgHC{ZYPzbY9v MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzN{izO|goRjJ|MUe4N|c5RC:jPh?=
U266 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13mRlAvODFvMUCg{txO NWHvXG5[PDkkgJno Mlj0SG1UVw>? MoqybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NU\1dW5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVIxODhpPkKyOVUzODB6PD;hQi=>
CRBN60 NV;5elVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvjSnVMOC5yMT2xNEDPxE1? MkHOOFjjiImq Mnu1SG1UVw>? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Ml33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUKwNFgoRjJ{NUWyNFA5RC:jPh?=
CRNB75 M3m4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW1ZnhjOC5yMT2xNEDPxE1? NWH2c2t3PDkkgJno MX3EUXNQ M1rObIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3MkCwPEc,OjJ3NUKwNFg9N2F-
MM.1S M1jjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHVZ21TOC5yMT2xNEDPxE1? MWO0PQKBkWh? MVTEUXNQ NUPYUY1Xe2mpbnnmbYNidnSueTDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGG2IHPvcoNmdnS{YYTpc45{KGG|IHzve{BieyByLkCx{txO M1\KR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
OPM2 NEDmS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PmNVAvODFvMUCg{txO NYXGSXdYPDkkgJno NGH6epVFVVOR M2PUPJNq\26rZnnjZY51dHliaX7obYJqfHNicILvcIln\XKjdHnvckBifCClb37j[Y51emG2aX;ud{BieyCub4egZZMhOC5yMd88US=> M3q1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
MM.1S MWXGeY5kfGmxbjDBd5NigQ>? M4qwclExKM7:TR?= NUHNT3pqPzJiaB?= NXfnWZY3TE2VTx?= NHj2U5J{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> NWfibnJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPFk{OjdpPkKxN|g6OzJ5PD;hQi=>
H929 NYq1VoJ7TnWwY4Tpc44hSXO|YYm= NHrp[GwyOCEQvF2= NG[2WZg4OiCq M{TESmROW09? NWS2NllNe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXygc4YhSy:HQmFOtkBqe2:ob4Ltd:Kh NETFRlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
OPM2 NEDrcZpHfW6ldHnvckBCe3OjeR?= Ml7MNVAh|ryP M1HrVlczKGh? NH6xfVJFVVOR M2TGTpNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> MlrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
CT26 MWTGeY5kfGmxbjDBd5NigQ>? M3vrUVEwOTBizszN MXmyOEBp M3TQbJJm\HWlZYOgeIhmKG63bXLldpMhd2ZibHn2[UBkd2yxbnnld:Kh MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ|OEm3O{c,OTl4M{i5O|c9N2F-
T-cells MnnuSpVv[3Srb36gZZN{[Xl? MWGyJJRwKDNiZHH5dy=> NH7zTFRKdmirYnn0bY9vKG:oIFnMMVIheHKxZIXjeIlwdiCrbjDoeY1idiCWIHPlcIx{KG2nYYP1doVlKGGodHXyJFIhfG9iMzDkZZl{KGK7IFXMTXNCNCCHQ{WwJF0hOC5yMEig{txONg>? M37oRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MU[4NFE6Lz5{M{G2PFAyQTxxYU6=
DF15 MXHGeY5kfGmxbjDhd5NigQ>? NVnIUZZ5PCCqcoO= MXjJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIFqd2yxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlAzOiEQvF2u MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
DF15 M3X1OmZ2dmO2aX;uJIF{e2G7 NVLGNHdtPCCqcoO= MX\JcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIls[XKxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlAzPCEQvF2u NV3ObYRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 NXrYNVZnTnWwY4Tpc44h[XO|YYm= MmHrOEBpenN? MX3JcoR2[3Srb36gc4YhS1KOND;DVmJPKHWkaYH1bZRqdiCuaXfhd4UudWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDwUG9ENWWSTD30ZYdo\WRiYXnvcI9{KGGodHXyJFQhcHK|IHL5JIx2dWmwZYPj[Y5k\SCkYYPl[EBj\XSjLXfhcIFkfG:|aXThd4Uh\W68eX3lJIZz[WevZX70ZZRqd25iY3;tdIxmdWWwdHH0bY9vKGG|c3H5MEBGSzVyIE2gNE4xOjdizszNMi=> NYDRZlFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVg2ODdpPkK4N|U5PTB5PD;hQi=>
NAMALWA MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MonNO|IhcHK| NX3ZU2s{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDORW1CVFeDIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzOKXYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFczKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6wN{DPxE1w MlO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNkiwNVkoRjJ|MU[4NFE6RC:jPh?=
HeLa NFTPS3JHfW6ldHnvckBie3OjeR?= M1jGOWlvcGmkaYTpc44hd2ZiSVytNU1idHCqYT3pcoR2[2WmIF7GMYtieHCjQjDhZ5RqfmG2aX;uJIlvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgZoxw[2urbnegc4YheDVyL4C2OUBvfWOuZXHyJJRz[W6|bH;jZZRqd25uIFnDOVAhRSBzLkK3JO69VS5? M{L3SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OES1PFUxLz5zN{i0OVg2ODxxYU6=
DF15 NV\oW3VTTnWwY4Tpc44h[XO|YYm= MUWwMlAyKHSxIEGgeW0> MkTyOUBpenN? M{nBNGlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDheEAxNjBzIITvJFEhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NUfoPXFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 MVXGeY5kfGmxbjDhd5NigQ>? M3\a[FAvODFidH:gNUB2VQ>? MV:1JIhzew>? NWi1TJNmUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHnrZZJweyCmZXfyZYRifGmxbjDpckBpfW2jbjDPVG0zKGOnbHzzJIF1KDBwMEGgeI8hOSC3TTDh[pRmeiB3IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MmewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
DF15 M1XJN2Z2dmO2aX;uJIF{e2G7 MkSxNE4xOSC2bzCxJJVO MoDDOUBpenN? NF7XRWNKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiaXvhdo9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5yMTD0c{AyKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NYjXe|VoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 M{HGRWZ2dmO2aX;uJIF{e2G7 MXqwMlAyKHSxIEGgeW0> MnPWOUBpenN? MljTTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCRUF2yJINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ M3Xj[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
アッセイ
Methods Test Index PMID
Western blot CEBPβ ; IKZF1 / IKZF3 / UBE2G1 / CRBN 21389327 30234487
Immunofluorescence IKZF1 29496670
体内試験

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

  • Inhibition of TNF-α synthesis:

    TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.

細胞試験:

[4]

  • 細胞株:Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • 濃度: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • 反応時間:24 or 48 hours
  • 実験の流れ:

    For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.

動物試験:

[4]

  • 動物モデル:Disseminated lymphoma-bearing SCID mice
  • 投薬量:0.5 mg/kg
  • 投与方法:Injection i.p.

溶解度 (25°C)

体外

体内

左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。

3mg/mL

化学情報

分子量 273.24
化学式

C13H11N3O4

CAS No. 19171-19-8
Storage 3年 -20°C
2年 -80°C in solvent
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04902443 Recruiting Drug: Pomalidomide|Drug: Nivolumab Viral Associated Malignancies|Kaposi Sarcoma|EBV/KSHV-associated Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 10 2021 Phase 1
NCT04577755 Recruiting Drug: Pomalidomide Skin Kaposi Sarcoma National Cancer Institute (NCI) July 1 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

回答
S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

質問2:
I would like to know if the pomalidomide is racemic or optically active?

回答
Our S1567 Pomalidomide is racemic.

Tags: Pomalidomide (CC-4047)を買う | Pomalidomide (CC-4047) ic50 | Pomalidomide (CC-4047)供給者 | Pomalidomide (CC-4047)を購入する | Pomalidomide (CC-4047)費用 | Pomalidomide (CC-4047)生産者 | オーダーPomalidomide (CC-4047) | Pomalidomide (CC-4047)化学構造 | Pomalidomide (CC-4047)分子量 | Pomalidomide (CC-4047)代理店